![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
HAL Allergy |
Information provided by: | HAL Allergy |
ClinicalTrials.gov Identifier: | NCT00422149 |
To show that treatment with SUBLIVAC® Grasses is clinically effective by means of reduction in allergic symptoms and/or use of allergic symptomatic medication in subjects suffering from IgE mediated allergic complaints triggered by grass pollen.
Condition | Intervention | Phase |
Rhinitis, Allergic, Seasonal Conjunctivitis, Allergic |
Drug: SUBLIVAC® Grasses/Placebo treatment Drug: SUBLIVAC® Grasses treatment Drug: Placebo treatment |
Phase III |
MedlinePlus related topics: | Allergy Hay Fever |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Twin SUBLIVAC® Grasses Clinical Efficacy Study |
Enrollment: | 350 |
Study Start Date: | September 2006 |
Estimated Study Completion Date: | November 2009 |
Estimated Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Active Comparator
SUBLIVAC® Grasses treatment
|
Drug: SUBLIVAC® Grasses/Placebo treatment
SUBLIVAC® Grasses/Placebo treatment
Drug: SUBLIVAC® Grasses treatment
SUBLIVAC® Grasses treatment
|
2: Placebo Comparator
Placebo treatment
|
Drug: SUBLIVAC® Grasses/Placebo treatment
SUBLIVAC® Grasses/Placebo treatment
Drug: Placebo treatment
Placebo treatment
|
Indication under study: IgE mediated allergic disorders triggered by grass pollen.
Number of centres: approximately 50.
Study period planned: Q2-2006 until Q3-2008 Analysis after one exposed season (2007); based on the outcome the study will be stopped or continued for another season.
Subject selection criteria: Seasonal rhinitis and/or rhinoconjunctivitis with or without mild asthma (FEV1 > 70%) related to grass pollen, age 12 years or older.
Dosage schedule: Start with two drops daily of SUBLIVAC® and increase by two drops daily, until the maintenance dose of 10 drops SUBLIVAC® GrassesSUBLIVAC® Grasses is reached.
Route of administration: Sublingual application (drops are to be held underneath the tongue for 2-3 minutes and then will be swallowed).
Duration of treatment: 6 to 12 months blinded per subject . Efficacy parameters
Ages Eligible for Study: | 12 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
![]() |
Show 60 Study Locations |
HAL Allergy |
Principal Investigator: | R Peter, Prof.Dr.med | Zentrum für Klinische Forschung, Helholzstrasse 8/1, 89081 Ulm, Germany |
Responsible Party: | HAL Allergy BV ( H.A.J. Kleinjans ) |
Study ID Numbers: | SG/0021, EudraCTnr: 2005-005175-16 |
First Received: | January 12, 2007 |
Last Updated: | March 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00422149 |
Health Authority: | Germany: Paul-Ehrlich-Institut; Netherlands: Medical Ethics Review Committee (METC); Poland: Ministry of Health; Belgium: Institutional Review Board |
|
|
|
|
![]() |